Last reviewed 2026-06-10 · How we verify

Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy — Treatment Landscape & Competitive Intelligence

Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDU

Marketed treatment landscape

Approved drugs treating Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Pfizer · 1 drug in Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy:

• Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy treatment updates — RSS
• Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy treatment updates — Atom
• Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy treatment updates — JSON

Cite this brief

Drug Landscape (2026). Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/adjuvant-treatment-of-hormone-receptor-positive-invasive-breast-cancer-in-postmenopausal-women-with-disease-recurrence-or-metastasis-after-2-3-years-of-tamoxifen-therapy. Accessed 2026-06-10.

Related

• Adjuvant treatment of hormone receptor-positive invasive breast cancer in postmenopausal women with disease recurrence or metastasis after 2-3 years of tamoxifen therapy full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing